"We value PRR on the basis of a successful Phase IIb trial for CVac leading to a licensing deal for the product. Our 60 cent target price for PRR is at the lowpoint of our base case $0.63 / optimistic case $1.12 per share probability weighted DCF valuation range. We think that the current market capitalisation of Dendreon (Nasdaq: DNDN) of US$5.9bn is indicative of the potential of PRR. Dendreon’s Provenge cellular therapy, which is similar to
PRR’s, gained FDA approval in late April 2010."
http://www.swiftpage4.com/CampResource/2W0VYSM9HVFHYD2G/BIO/text.pdf
This quote was taken from a brokers report from 2010!
A LOT of boxes have been ticked since then!!!
"We value PRR on the basis of a successful Phase IIb trial for...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
-0.010(2.50%) |
Mkt cap ! $566.5M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 39.5¢ | 38.5¢ | $997.5K | 2.559M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 85852 | 38.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 75389 | 4 |
View Market Depth
| Last trade - 16.10pm 04/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |